Atlas Trials

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Clinical trial NCT05132101 · COMPLETED

Trial details

NCT number
NCT05132101
Sponsor
Pfizer
Status
COMPLETED
Study type
OBSERVATIONAL
Metastatic Breast Cancer
Start date
2021-12-20
Primary completion
2022-03-14
Enrollment
2758

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.